Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025
Merck shares jumped about 4% to $101.97 on Monday after Wells Fargo upgraded the stock and raised its price target to $125. The move followed new data on Merck’s hematology pipeline, another FDA approval for Keytruda in bladder cancer, and increased institutional buying. MRK traded at its highest level since January, with technical indicators signaling overbought conditions.